50
Participants
Start Date
December 31, 2011
Primary Completion Date
October 31, 2013
Study Completion Date
October 31, 2013
pneumococcal conjugate 13 valent vaccine
"Pneumococcal polysaccharide conjugate vaccine(13-valent adsorbed) conjugated to CRM197 carrier protein and adsorbed on aluminum phosphate (0.125 mg of aluminum).~Pharmaceutical form: suspension for injection. Dosage: 0.5 ml, containing 2.2 g of polysaccharide for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, and 4.4 micrograms for serotype 6B.~Prevenar 13 is administered in two doses,each of 0.5 ml, with an interval of 2 months, injected intramuscularly in the deltoid muscle of the arm."
UOC Malattie Infettive Universitarie, Policlinico Le Scotte, Siena
Istituto di Clinica delle Malattie Infettive, Policlinico Gemelli, Roma
Ministry of Education, Universities and Research, Italy
OTHER
University of Siena
OTHER